[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634124":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":11,"studyPopulation":11,"armGroups":33,"interventions":46,"overallOfficials":54,"centralContacts":58,"locations":66,"responsibleParty":80,"collaborators":11,"id":82,"slug":11,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":11,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":11,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Frequency of Adverse Events",null,"Serious adverse events (SAEs) after signing of ICF up to Month 12; nonserious AEs after first dose of study drug up to Month 12",[14,17,20],{"measure":15,"description":11,"timeFrame":16},"Change from Baseline Inflammatory Markers in Plasma","Baseline up to Month 9",{"measure":18,"description":11,"timeFrame":19},"Concentration of ALN-4915 in Plasma","Predose up to Day 3",{"measure":21,"description":11,"timeFrame":22},"Concentration of ALN-4915 in Urine","Predose up to Day 1",{"allocation":24,"interventionModel":25,"interventionModelDescription":11,"primaryPurpose":26,"observationalModel":11,"timePerspective":11,"maskingInfo":27},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":28,"maskingDescription":11,"whoMasked":29},"TRIPLE",[30,31,32],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[34,40],{"label":35,"type":36,"description":37,"interventionNames":38},"ALN-4915","EXPERIMENTAL","Participants will be administered a single dose of ALN-4195.",[39],"Drug: ALN-4915",{"label":41,"type":42,"description":43,"interventionNames":44},"Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo.",[45],"Drug: Placebo",[47,51],{"type":48,"name":35,"description":49,"armGroupLabels":50,"otherNames":11},"DRUG","ALN-4915 will be administered subcutaneously (SC)",[35],{"type":48,"name":41,"description":52,"armGroupLabels":53,"otherNames":11},"Placebo will be administered SC",[41],[55],{"name":56,"affiliation":5,"role":57},"Medical Director","STUDY_DIRECTOR",[59,64],{"name":60,"role":61,"phone":62,"phoneExt":11,"email":63},"Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":60,"role":61,"phone":65,"phoneExt":11,"email":63},"1-877-256-9526",[67],{"facility":68,"status":69,"city":70,"state":11,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":11},"Clinical Trial Site","RECRUITING","London","NW10 7EW","United Kingdom","UK",{"type":75,"coordinates":76},"Point",[77,78],-0.12574,51.50853,{"lat":78,"lon":77},{"type":81,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100634124",false,"NCT07535606","A Study to Evaluate ALN-4915 in Adult Healthy Volunteers","A Phase 1, Randomized, Double-Masked, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-4915 in Adult Healthy Volunteers","Inclusion Criteria:\n\n* Is willing and able to complete all study assessments\n\nExclusion Criteria:\n\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>upper limit of normal (ULN)\n* Has total bilirubin \\>ULN\n* Has no history of invasive infection by an encapsulated organism\n* Has no known complement or immunologic deficiency",true,"ALL","18 Years","65 Years",{"count":93,"type":94},44,"ESTIMATED","INTERVENTIONAL",[97],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.",[100],"Healthy Volunteers",[102,103],"siRNA","RNAi","2026-06-10",{"date":106,"type":107},"2026-06-12","ACTUAL",{"date":109,"type":107},"2026-03-02",{"date":111,"type":94},"2027-07-31",{"name":5,"class":6},1]